Publications | Centro de Investigaciones Biológicas Margarita Salas - CIB Margarita Salas

Back

Tosat-Bitrián C, Palomo V. [2020]. CdSe quantum dots evaluation in primary cellular models or tissues derived from patients. Nanomedicine. 30:102299

Palomo V, Nozal V, Rojas-Prats E, Gil C, Martinez A. [2020]. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Br J Pharmacol

Palomo V, Tosat-Bitrian C, Nozal V, Nagaraj S, Martin-Requero A, Martinez A. ACS Chem Neurosci. [2019]. TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis

Palomo V, Cistrone PA, Zhan N, Palui G, Mattoussi H, Dawson PE. [2018]. Efficient Assembly of Quantum Dots with Homogenous Glycans Derived from Natural N-Linked Glycoproteins. Bioconjug Chem. 29, 3144-3153.

Sánchez-Cruz A, Villarejo-Zori B, Marchena M, Zaldivar-Díez J, Palomo V, Gil C, Lizasoain I, de la Villa P, Martínez A, de la Rosa EJ, Hernández-Sánchez C. [2018]. Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Mol Neurodegener. 13, 19.

Medina-Rodríguez EM, Bribián A, Boyd A, Palomo V, Pastor J, Lagares A, Gil C, Martínez A, Williams A, de Castro F. [2017]. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep. 7, 43545.

Palomo V, Perez DI, Roca C, Anderson C, Rodríguez-Muela N, Perez C, Morales-Garcia JA, Reyes JA, Campillo NE, Perez-Castillo AM, Rubin LL, Timchenko L, Gil C, Martinez A. [2017]. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. J Med Chem. 60, 4983-5001.

Palomo V, Martinez A. [2017]. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). xpert Opin Ther Pat. 27, 657-666.

Marchena M, Villarejo-Zori B, Zaldivar-Diez J, Palomo V, Gil C, Hernández-Sánchez C, Martínez A, de la Rosa EJ. [2017]. Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. J Enzyme Inhib Med Chem. 32, 522-526.

Polonskaya Z, Deng S, Sarkar A, Kain L, Comellas-Aragones M, McKay CS, Kaczanowska K, Holt M, McBride R, Palomo V, Self KM, Taylor S, Irimia A, Mehta SR, Dan JM, Brigger M, Crotty S, Schoenberger SP, Paulson JC, Wilson IA, Savage PB, Finn MG, Teyton L. [2017]. T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest. 127,1491-1504

Pérez-Domper P, Palomo V, Gradari S, Gil C, de Ceballos ML, Martínez A, Trejo JL. [2017]. The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology. 116, 174-187.

de Munck E, Palomo V, Muñoz-Sáez E, Perez DI, Gómez-Miguel B, Solas MT, Gil C, Martínez A, Arahuetes RM. [2016]. Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. PLoS One. 11, e0162723.

Palomo V, Díaz SA, Stewart MH, Susumu K, Medintz IL, Dawson PE. [2016]. 3,4-Dihydroxyphenylalanine Peptides as Nonperturbative Quantum Dot Sensors of Aminopeptidase. ACS Nano. 10, 6090-9.